565P Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up

Autor: Brown, C.J., O'Callaghan, C., Loree, J.M., Moloo, H., Auer, R., Jonker, D., Raval, M., Ma, G., Caycedo-Marulanda, A., Simianu, V., Patel, S., Pitre, L., Helewa, R., Gordon, V.L., Neumann, K., Bosse, D., Krahn, M.J., Tu, D., Kennecke, H.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S462-S463

Im alten Ratskeller von Berlin

Autor: Faensen, B., Hofmann, M., Kennecke, H., Schumann, D.

Publikováno v: Archäologie in Deutschland, 2011 May 01(3), 48-49.

Externí odkaz: https://www.jstor.org/stable/26319577

Does HER2 status influence locoregional failure rates in breast cancer patients treated with mastectomy for pT1–2pN0 disease?

Autor: Kwan, W. ^*, Al-Tourah, A.J., Speers, C., Woods, R., Kennecke, H., Olivotto, I.A.

Publikováno v: In Annals of Oncology May 2010 21(5):988-993

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Autor: Yao, James C, Fazio, Nicola, Singh, Simron, Buzzoni, Roberto, Carnaghi, Carlo, Wolin, Edward, Tomasek, Jiri, Raderer, Markus, Lahner, Harald, Voi, Maurizio, Pacaud, Lida Bubuteishvili, Rouyrre, Nicolas, Sachs, Carolin, Valle, Juan W, Delle Fave, Gianfranco, Van Cutsem, Eric, Tesselaar, Margot, Shimada, Yasuhiro, Oh, Do-Youn, Strosberg, Jonathan, Kulke, Matthew H, Pavel, Marianne E, Raderer, M, Pall, G, Van Cutsem, E, Borbath, I, Geboes, K, Peeters, M, Asmis, T, Kocha, W, Rayson, D, Ruether, J, Singh, S, Sideris, L, Kennecke, H, Wang, J, Shen, L, Xu, J, Qian, J, Jia, L, Maya, L F, Melichar, B, Sedlackova, E, Tomasek, J, Pavel, M, Bojunga, J, Malfertheiner, P, Vogel, A, Weber, M, Hörsch, D, Kaltsas, G, Papai, Z, Toth, M, Carnaghi, C, Luppi, G, Fazio, N, Tomassetti, P, Delle Fave, G, Cartenì, G, Buzzoni, R, Barone, C, Berruti, A, Giuffrida, D, Tortora, G, Di Costanzo, F, Tafuto, S, Ito, T, Okita, N, Komoto, I, Kattan, J, Shamseddine, A, Tesselaar, M, Jarzab, B, Ruchala, M, Vladimirova, L, Raef, H, Salek, T, Ruff, P, Kim, T W, Park, Y S, Oh, D-Y, Lee, M-A, Choi, H J, Capdevila, J, Salazar, R, Zoilo, J J R, Chen, J-S, Wu, C-C, Chen, Y-Y, Chao, Y, Yeh, K-H, Sriuranpong, V, Thongprasert, S, Turna, H, Sevinc, A, Valle, J, Sarker, D, Reed, N, Cave, J, Frilling, A, Corrie, P, Fanta, P, Yao, J, Strosberg, J, Verma, U, Libutti, S, Natale, R, Pommier, R, Lubner, S, Starodub, A, Kulke, M, Sigal, D, Polite, B, Lieu, C, Hande, K, Reidy-Lagunes, D, McCollum, A, Forero, L

Publikováno v: Lancet (London, England). 387(10022)

Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population.In

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0306601f2e33d5855e8b347e9fcdca53
https://pubmed.ncbi.nlm.nih.gov/27479568